0000899243-19-016722.txt : 20190612 0000899243-19-016722.hdr.sgml : 20190612 20190612210052 ACCESSION NUMBER: 0000899243-19-016722 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190610 FILED AS OF DATE: 20190612 DATE AS OF CHANGE: 20190612 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kemmerly David L CENTRAL INDEX KEY: 0001673554 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 19894751 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-10 0 0000896262 AMEDISYS INC AMED 0001673554 Kemmerly David L 3854 AMERICAN WAY, SUITE A BATON ROUGE LA 70816 0 1 0 0 See Remarks Common Stock 2019-06-10 4 M 0 1875 27.35 A 17107 D Common Stock 2019-06-10 4 M 0 3125 27.35 A 20232 D Common Stock 2019-06-10 4 M 0 3125 27.35 A 23357 D Common Stock 2019-06-10 4 S 0 8125 117.77 D 15232 D Common Stock 445 I Through 401(k) Plan Stock Option (right to buy) 27.35 2019-06-10 4 M 0 1875 0.00 D 2025-05-01 Common Stock 1875 0 D Stock Option (right to buy) 27.35 2019-06-10 4 M 0 3125 0.00 D 2025-05-01 Common Stock 3125 3125 D Stock Option (right to buy) 27.35 2019-06-10 4 M 0 3125 0.00 D 2025-05-01 Common Stock 3125 6250 D The total amount of shares beneficially owned includes 219 shares held in an employee stock purchase plan account. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.46 to $118.26, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. The information in this report is based on a plan statement dated as of March 31, 2019. On May 1, 2015, the reporting person was granted an option to purchase 37,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2016 were met, resulting in vesting of the option as to 9,375 shares (the "2016 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2016 Tranche Options vested on May 1, 2017, one-third of the 2016 Tranche Options vested on May 1, 2018 and one-third of the 2016 Tranche Options vested on May 1, 2019. After the transaction being reported herein, the reporting person has exercised all of the 2016 Tranche Options. On May 1, 2015, the reporting person was granted an option to purchase 37,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2017 were met, resulting in vesting of the option as to 9,375 shares (the "2017 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2017 Tranche Options vested on May 1, 2018, one-third of the 2017 Tranche Options vested on May 1, 2019 and one-third of the 2017 Tranche Options will vest on May 1, 2020, assuming the reporting person remains continuously employed by the Issuer on such date, subject to certain pro-rated vesting provisions as provided in the award agreement for the options. After the transaction being reported herein, the reporting person has exercised 6,250 of the 2017 Tranche Options. On May 1, 2015, the reporting person was granted an option to purchase 37,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2018 were met, resulting in vesting of the option as to 9,375 shares (the "2018 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2018 Tranche Options vested on May 1, 2019, and two-thirds of the 2018 Tranche Options will vest on May 1, 2020, assuming the reporting person remains continuously employed by the Issuer on such date, subject to certain pro-rated vesting provisions as provided in the award agreement for the options. After the transaction being reported herein, the reporting person has exercised 3,125 of the 2018 Tranche Options. General Counsel and Senior Vice President of Government Affairs /s/ Jennifer R. Guckert, pursuant to a power of attorney 2019-06-12